Global Antibacterial Drugs Market 2017-2027

©notice
This material is copyright by visiongain. It is against the law to reproduce any of this material without the prior
written agreement of visiongain.You cannot photocopy, fax, download to database or duplicate in any other way
any of the material contained in this report. Each purchase and single copy is for personal use only.
Global Antibacterial Drugs Market
2017-2027
Cephalosporins, Penicillins, Fluoroquinolones, Macrolides,
Carbapenems and Others

www.visiongain.com
Contents
1. Report Overview
1.1 Overview of Findings
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by This Analysis
1.5 Who is This Study For?
1.6 Research and Analysis Methods
1.7 Frequently Asked Questions (FAQs)
1.8 Some Associated Reports
2. Introduction to Antibacterial Drugs
2.1 Types of Bacterial Infection
2.2 Main Bacteria Causing Infections in Human Beings
2.3 Incidence and Mortality Profiles for Common Bacterial Infection
2.4 Treating Infections
2.4.1 The History of Antibacterial Drug Development
2.4.2 Mechanisms of Action
2.4.3 Leading Classes of Antibacterial Medicines
2.4.3.1 Cephalosporins
2.4.3.2 Penicillins
2.4.3.3 Carbapenems

www.visiongain.com
Contents
2.4.3.4 Fluoroquinolones
2.4.3.5 Macrolides
2.4.4 Antibacterial Drug Resistance
3. Antibacterial Drugs: World Market 2017-2027
3.1 Antibacterial Drugs Revenues Plateau between 2011 and 2016
3.2 Antibacterial Agents - Market Segmentation
3.3 Antibacterial Drugs Market Forecast 2017-2027: Decline in Revenues for
Fluoroquinolones
3.4 Drivers and Restraints in the Antibacterial Drugs Market, 2017-2027
3.5 Generic Erosion and Prescription Control Will Limit Market Growth
3.6 Changes in that Industry Sector’s Market Shares, 2017-2027
3.7 Pfizer is the Leader in the Antibacterial Drugs Market, 2016
3.8 Fragmented Market to Fracture Further
4. Cephalosporins Market Forecast 2017-2027
4.1 Cephalosporins Market 2016 – No Dominant Brands
4.1.1 Late-Stage Cephalosporins to Gain Market Share Between 2017 and 2027
4.1.2 Basilea, Merck, Actavis and AstraZeneca to Lead the Cephalosporins Market
Between 2017 and 2027
4.1.3 Drivers and Restraints on the Cephalosporins Market, 2017-2027
4.1.4 Cephalosporins Lack Market Exclusivity
4.1.5 Strong Pipeline for Novel Cephalosporins

www.visiongain.com
Contents
4.1.6 Rocephin (Roche) – The Only Treatment for Gonorrhoea in the US
4.1.6.1 Off Patent but Still Effective
4.1.6.2 Declining Revenues Owing to Competition - Forecast 2017-2027
4.1.7 Sulperazon – India’s Leading Treatment for RTIs and UTIs
4.1.7.1 Continued Growth in the Emerging Markets, Revenue Forecast 2017-2027
4.1.8 Zinnat/Ceftin – GSK’s Established Cephalosporin
4.1.8.1 Continued Decline in Revenue - Forecast 2017-2027
4.1.9 Meiact – A Broad Range Community Antibiotic
4.1.9.1 Spectracef Sales in the US Leads to Pass the Product
4.1.9.2 Competition in Japan to Hinder Growth – Revenue Forecast 2017-2027
4.1.10 Flomox - Shionogi’s Third-Generation Cephalosporin
4.1.10.1 Patent Issues and Litigation
4.1.10.2 Genericization and Safety to Restrict Sales - Forecast 2017-2027
4.1.11 Zinforo/Teflaro (Ceftaroline Fosamil): The First of the Fifth- Generation
Cephalosporins
4.1.11.1 Unmet Needs in Pneumonia to Drive Growth - Revenue Forecast 2017-2027
4.1.12 Zeftera (ceftobiprole): Approved for Pneumonia in Europe
4.1.12.1 Future Sales Dictated by US Approval - Revenue Forecast 2017-2027
4.1.13 CXA-201 (Ceftolozane-Tazobactam): The Next Blockbuster Antibacterial
4.1.13.1 Broad Label and Spectrum of Activity Leads to Rapid Uptake - Revenue
Forecast 2017-2027

www.visiongain.com
Contents
4.1.14 CAZ-AVI (Ceftazidime-Avibactam): Approved in 2015
4.1.14.1 Competition from CXA-201 to Limit Sales - Forecast 2017-2027
5. Penicillins Market Forecast 2017-2027
5.1 Generics and Augmentin Dominate the Penicillins Market in 2016
5.2 Augmentin to Lose its Dominance over the Coming 10 Years - Market Shares for
Penicillin Drugs, 2017-2027
5.3 Penicillin Antibacterial Drugs: Market Forecast 2017-2027
5.4 Drivers and Restraints for the Penicillin Market 2017-2027
5.5 Augmentin – Blockbuster Facing Generic Competition
5.5.1 Augmentin – Challenges in Some Countries
5.5.2 Stable Revenues Regardless of Generic Competition
5.5.3 Revenue Forecast 2017-2027
5.6 Zosyn/Tazocin (Piperacillin-Tazobactam) - Pneumonia Therapeutic
5.6.1 Patent Expiry and Revenue Extension for Pfizer
5.6.2 Historic and Current Revenue Performance
5.7 Unasyn – Gram-negative and Positive Antibiotic
5.7.1 Falling Revenues - Forecast 2017-2027
5.8 Amoxil (Amoxicillin) – A Historic Antibacterial Brand
5.8.1 Marginal Decline in Revenue - Forecast 2017-2027
5.9 Generic Amoxicillin

www.visiongain.com
Contents
5.10 Generic Amoxicillin-Clavulanic Acid
6. Fluoroquinolone Market Forecast 2017-2027
6.1 The Fluoroquinolone Market 2016
6.2 Changing Market Share for Fluoroquinolone Antibacterial Drugs, 2017-2027
6.3 Fluoroquinolone Antibacterial Drugs: Market Forecast 2017-2027
6.4 Trends in the Fluoroquinolone Market
6.4.1 Safety Fears for Fluoroquinolones
6.4.2 Avelox Patent Cliff
6.4.3 Inhaled Fluoroquinolone Formulations
6.5 Fluoroquinolone Market Forecast 2017-2027
6.6 Avelox
6.6.1 Safety Profile Hampers Sales
6.6.2 Generic Competition
6.7 Cravit and Levaquin
6.7.1 Generic Competition Affecting Revenue Worldwide
6.7.2 Lifecycle Management for Cravit and Levaquin

www.visiongain.com
Contents
6.8 Vigamox
6.8.1 Branded and Generic Challenges 2011-2016
6.8.2 Moxeza: A Next-Generation Form of Vigamox
6.9 Ciprodex and Cipro – Two Preparations of Ciprofloxacin
6.9.1 Ciprodex: A Second-Generation Ophthalmic Antibiotic
6.9.1.1 Revenue Forecast 2017-2027
6.9.2 Cipro Revenue Forecast 2017-2027: Continued Generic Erosion
6.10 Geninax
6.11 Delafloxacin
7. Macrolide Market Forecast 2017-2027
7.1 Macrolide Market in 2016
7.2 Changing Market Share for Macrolides, 2017-2027
7.3 Macrolide Antibacterial Drugs: Market Forecast 2017-2027
7.4 Trends in the Macrolide Market
7.5 Biaxin/Clarith
7.5.1 Past Revenue 2011-2015
7.5.2 Lifecycle Management for Continued Market Presence

www.visiongain.com
Contents
7.6 Zithromax
7.6.1 Concerns Over Safety and Marketing in the US
7.6.2 Effectiveness in Drug-Resistant Strains
7.7 Dalacin
7.8 Dificid
7.8.1 Rapid Uptake Slowed by High Cost
7.8.2 New Approvals and Expanded Indications
7.9 Solithromycin
8. Carbapenem Market Forecast 2017-2027
8.1 Carbapenem Market 2016
8.2 Changing Market Share for Carbapenems, 2017-2027
8.3 Carbapenem Antibacterial Drugs: Market Forecast 2017-2027
8.4 Trends in the Carbapenem Market
8.4.1 Rising Prevalence of Carbapenemases and β-Lactamases
8.4.2 No New Carbapenems in Late-Stage Trials

www.visiongain.com
Contents
8.5 Merrem/Meropenem
8.5.1 Generics Affecting Revenue Worldwide
8.6 Primaxin
8.6.1 Combination Therapy for Lifecycle Management
8.6.2 Historic and Current Revenues
8.7 Invanz
8.8 Doribax
8.8.1 Doribax in HAP and VAP
8.8.2 Lifecycle Management in Japan and the Rest of the World
9. Other Antibacterial Drugs Forecast 2017-2027
9.1 The Market for Other Classes of Antibacterial Drugs
9.2 Changing Market Share for Fluoroquinolone Antibacterials 2017-2027
9.3 Other Antibacterials: Market Forecast 2017-2027
9.4 Trends in the Other Classes of Antibacterial Drugs
9.4.1 New Oxazolidinones Will Drive Growth
9.4.2 New Drug Classes to Drive Submarket Growth to 2027

www.visiongain.com
Contents
9.5 Zyvox – The Market Leading Antibacterial
9.5.1 MRSA Activity Driving Revenue Growth
9.5.2 Promise in Tuberculosis and Anthrax
9.5.3 Patents, Litigation, and Competition – When and Who Will Produce Generic
Linezolid?
9.5.4 Flat Growth to Patent Expiry, Revenue Forecast 2017-2027
9.6 Cubicin – The Leading Brand for ABSSSIs
9.6.1 Revenue Boosted by Approvals Worldwide
9.6.2 Patents, Litigation and Deals – How Long Will Market Exclusivity Last?
9.6.3 Sustained Growth through to 2021, Revenue Forecast 2017-2027
9.7 Tygacil – A Tetracycline with Many Approved Indications
9.7.1 Concerns Limiting Revenue Potential
9.7.2 Competition from Other Therapies Restricts Growth: Revenue Forecast 2017-2027
9.8 TOBI/TOBI Podhaler – The Market Leading Inhaler for Cystic Fibrosis
9.8.1 Historic and Current Revenue Performance
9.8.2 Approvals and Launches in New Markets to Drive Revenue Growth
9.8.3 Competition to Limit Long-term Growth, Revenue Forecast 2017-2027
9.9 Solodyn – A Treatment for Severe Acne
9.9.1 Generic Competition and Lifecycle Management
9.9.2 Limited Potential for Dermatology, Revenue Forecast 2017-2027
9.10 Vibativ – Limited Potential for Novel Lipoglycopeptide

www.visiongain.com
Contents
9.10.1 Astellas Ends its Collaboration with Theravance
9.10.2 Limited HAP Label in the US - Revenue Forecast 2017-2027
9.11 Sirturo – A New Option for Multi-Drug Resistant TB
9.11.1 Chronic Treatment Schedule and Emerging Demand Drive Revenue Growth,
Forecast 2017-2027
9.12 Tedizolid – Market Leading Follow-on to Zyvox?
9.12.1 Competition Increasing: Revenue Forecast 2017-2027
9.13 Oritavancin – An Antibiotic with a Novel PK Profile
9.13.1 Single Dose Differentiation to Deliver Market Share (%), Revenue Forecast 2017-
2027
9.14 Dalbavancin – Competing in a Crowded Indication
9.14.1 Sustained Growth Over the Coming 10 Years, Revenue Forecast 2017-2027
9.15 Surotomycin –Treatment for C. difficile
9.15.1 Delayed Launch to Limit Potential, Revenue Forecast 2017-2027
9.16 Nemonoxacin – Taiwan’s Global Antibacterial Drug
9.16.1 Slow Initial Growth to Accelerate with US Approval, Revenue Forecast 2017-2027
10. The Leading National Markets 2017-2027
10.1 US and China Dominate the Global Antibacterial Market, But for Different Reasons
10.2 Above-Average Growth in US: Regional Forecasts 2017-2027
10.3 China to Slump in Market Share, While Brazil and India Push on
10.4 Incidence of Infection by Country, 2016

www.visiongain.com
Contents
10.4.1 Incidence of Pneumonia in National Markets – Pneumonia Predominant in America
10.4.2 Incidence of Community Acquired Urinary Tract Infections in National Markets –
High Incidence Rates in the UK, US and Spain
10.4.3 Incidence of Bacterial Skin and Skin Structure Infections in National Markets –
High Potential in the US
10.4.4 Incidence of Upper Respiratory Tract Infections in National Markets – Europe
Leads the Way
10.5 Antibacterial Drug Consumption by Country, 2016
10.5.1 Antibacterial Drug Consumption in the Major National Markets
10.5.2 Antibacterial Drug Consumption in Some Other National Markets
10.6 The Antibacterials Market in the US
10.6.1 Continued Dominance of the US Market
10.7 The European Union Forms Second Largest Regional Market
10.7.1 Marginal Expansion in Antibacterial Spending – Market Forecast 2017-2027
10.7.2 Action to Encourage Antibacterial Drug Development in the EU
10.7.3 Italy Continues to Lead the Way in Antibiotic Use
10.7.4 The French Fascination with Expensive Antibacterial Drugs
10.7.5 Germany – Europe’s Antibiotic Steward
10.7.6 Rising Use of Antibacterials Drugs in the UK
10.7.7 Spanish Antibacterials Market to Expand from 2021 to 2027
10.8 Japan – Still the Fourth Largest National Market
10.8.1 The Pause Before Growth in the Japanese Market

www.visiongain.com
Contents
10.9 Will South Korea Continue Its High Use of Antibiotics?
10.10 BRIC Nation Sales Still Expanding – Market Forecast 2017-2027
10.11 Chinese Antibacterial Market Bloated by Reported Overuse
10.11.1 Developing Antibacterials in China, for China
10.11.2 Governmental Controls Subdue Recent Growth – Market Forecast 2017-2027
10.12 Indian Market to Expand by 50% Over the Forecast Period
10.12.1 Restricting Antibiotic Use in India
10.12.2 Sustained Expansion of the Indian Market, Forecast 2017-2027
10.13 Brazilian Antibacterial Market to Double in Size
10.13.1 Brazilian Market to Be Driven by Drug Resistance
10.14 Russia: TB Prevalence to Stimulate Antibiotic Sales - Forecast 2017-2027
11. Antibacterials R&D Pipeline Review, 2017
11.1 Gram-Positive vs. Gram-Negative
11.2 Pipeline Dominated by Small Molecule Drugs
11.3 Leading Phase III Pipeline Treatment Candidates
11.3.1 Surotomycin – Broad C. difficile Treatment to Reduce Relapse
11.3.2 Baxdela (delafloxacin) – A Leading pH Activated, Broad Spectrum Fluoroquinolone
11.3.3 Solithera (solithromycin) – Fluroketolide with Favourable Side Effect Profile
11.3.4 Eravacycline – Treating Gram-Negative cUTIs and cIAIs
11.3.5 Plazomicin – Straight to PIII in Carbapenem Resistant Infections

www.visiongain.com
Contents
11.3.6 Omadacycline – Another Phase III-Ready Partnership
11.3.7 Relebactam – A Novel β-Lactamase Combination
11.3.8 CEM-102 (Fusidic acid) – Cempra’s Second Pipeline Candidate
11.3.9 BC-3781- Unique Mechanism of Action at 23S?
11.4 Leading Phase II Antibacterial Drug Candidates
11.4.1 Radezolid – Apparently on Melinta’s Back-Burner for Now
11.4.2 AFN-1252: Highly Specific S. Aureus Antibacterial
11.4.3 TD-1792 – A Russian Antibacterial Medicine
11.4.4 Brilacidin – A Novel Peptide Antibacterial Agent
11.5 Inhaled Antibiotics – Advantages in Lung Infections
11.5.1 Cayston: Competition for Novartis?
11.5.2 ARIKACE – Targeting P. aeruginosa
11.5.3 Aeroquin – Better than Podhaler?
11.5.4 BAYQ3939 – Developments for Cystic Fibrosis
11.5.5 NKTR-061: Targeting Intubated Pneumonia
11.5.6 Pulmaquin: A Second Ciprofloxacin Candidate
11.5.7 AeroVanc Targets MRSA Infections
11.5.8 Inhaled Amikacin-Fosfomycin – Adjunctive Therapy for VAP
11.6 Biologics – Truly Novel Antibacterial Therapeutics
11.6.1 MK-3415A: First Antibacterial mAb to the Market?
11.6.2 KB001A – The Leading Antibody Against P. aeruginosa

www.visiongain.com
Contents
11.6.3 Aridis Pharmaceuticals: Targeting P. aeruginosa and S. aureus
11.6.4 MEDI4893 - Early Stage mAb to S. Aureus
11.7 Other Classes
11.7.1 AZD0914 – Novel DNA Gyrase Inhibitor
11.7.2 MRX-I – Safer Oral Oxazolidinone to Treat MRSA
11.7.3 GSK2140944 – BTI Class of Antibiotics
11.7.4 Carbavance – to Treat CRE
12. Qualitative Analysis of the Antibacterial Industry and
Market, 2017
12.1 SWOT Analysis: Strengths, Weaknesses, Opportunities and Threats Affecting
Antibacterials, their Developers, Producers and Marketers
12.2 STEP Analysis: Social, Technological, Economic and Political Forces Affecting the
Antibacterial Drug Industry and Market
12.2.1 Social Factors
12.2.2 Technological Developments
12.2.3 Economic Pressures
12.2.4 Political Issues
12.3 Market is Well Established and Demand Will Remain Strong
12.4 High Prevalence of Bacterial Infection Worldwide
12.5 Worldwide Demand for Antibacterials
12.6 Animal Models of Infection are Highly Predictive Compared with Other Therapeutic
Fields

www.visiongain.com
Contents
12.7 Cutting into a Saturated Market
12.8 Superior Benefit over Generics?
12.9 Resistance – Nature’s Patent Expiry
12.10 Acute Treatment Limits Commercial Potential
12.11 Did Big Pharma Back Away from Antibacterial Drugs?
12.12 Resistance Will Continue to Present New Targets
12.13 First Biologic Antibacterials
12.14 Potential for Smaller Firms to Capitalise
12.15 Developing Preventative Vaccines Rather Than Treatments
12.16 Antibacterial Stewardship Reduces Usage
12.17 Clinical Confusion from Inconsistent Guidance Between Regulatory Bodies
12.17.1 Therapeutic Success in European Clinical Trials
12.17.2 Primary End Points in FDA Guidelines
12.18 Reduction in Hospital Infection Rates - Reducing Demand for Antibacterial Drugs
12.19 Enticing Antibacterial Drug Discovery – Push and Pull Incentives
12.19.1 GAIN act: Post-Development Pull Incentives in the US
12.19.2 ADAPT – Building on the GAIN act
12.19.3 EMA Update Guideline – Streamlining Clinical Trials in the EU
12.19.4 Push Incentives for Antibacterial Drug Discovery with Public Funding
12.19.5 IMI: Public-Private Collaboration with GSK and AstraZeneca
12.19.6 Public Finance Pumping Money into Antibacterial Development

www.visiongain.com
Contents
13. Antibacterial Drugs Market 2017 - 2027: Conclusions
13.1 Three Blockbuster Antibacterials in 2016 - Leading Brands
13.2 The Leading Branded Antibacterial Drugs in 2027
13.3 Signs of Life in the Antibacterial R&D Pipeline
13.4 Stemming the Tide of Antibacterial Drug Resistance
13.5 The Changing Face of Antibacterial Clinical Development
Appendices
Some Associated Visiongain Reports
Visiongain Report Sales Order Form
About Visiongain
Visiongain Report Evaluation Form

www.visiongain.com
Contents
List of Tables
Table 1.1 (Sample) Global Antibacterial Drugs Market: Revenue Forecasts by Sector
($bn), Annual Growth (%) and CAGR, 2017-2027
Table 2.1 Common Bacterial Infections and Their Causes
Table 2.2 Details of the ESKAPE Bacteria
Table 2.3 Leading Causes of Infectious Diseases Deaths Worldwide, 2010
Table 2.4 Mechanisms of Action for Antibacterial Drugs
Table 3.1 Antibacterial Drugs: Historic Global Market Size ($bn), Annual Growth (%), and
CAGR (%), 2011-2016
Table 3.2 Global Antibacterial Drug Market by Sector: Market Size ($bn) and Share (%),
2016
Table 3.3 Global Antibacterial Drugs Market: Revenue Forecasts by Sector ($bn), Annual
Growth (%) and CAGR, 2017-2027
Table 3.4 Antibacterial Drugs Market: Forecasted Sector Market Shares (%), 2017-2027
Table 3.5 Leading Branded Antibacterials Manufacturers: Revenues ($bn) and Market
Shares (%), 2016
Table 4.1 Leading Branded Cephalosporin Antibacterial Drugs: Important Facts
Table 4.2 Cephalosporin Market by Product: Revenue ($bn) and Market Share (%), 2016
Table 4.5 Cephalosporin Market Forecast by Product: Revenue ($bn), Annual Growth
(%), CAGR (%), 2017-2027
Table 4.6 Cephalosporin Market Forecast by Product: Market Share (%), 2017-2027

www.visiongain.com
Contents
Table 4.7 Rocephin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
Table 4.8 Sulperazon Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-
2027
Table 4.9 Zinnat/Ceftin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-
2027
Table 4.10 Meiact Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
Table 4.11 Flomox Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
Table 4.12 Zinforo in-vitro Antibacterial Activity: Gram-positive and Gram-negative
Bacteria
Table 4.13 Zinforo/Teflaro Forecast: Revenue ($bn), Annual Growth (%), CAGR (%),
2017-2027
Table 4.14 Zeftera Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
Table 4.15 Ceftolozane-tazobactam Forecast: Revenue ($bn), Annual Growth (%), CAGR
(%), 2017-2027
Table 4.16 Ceftazidime-Avibactam Forecast: Revenue ($bn), Annual Growth (%), CAGR
(%), 2017-2027
Table 5.1 Leading Branded Penicillin Drugs: Important Facts
Table 5.2 Penicillin Market by Product: Revenue ($bn) and Market Shares (%), 2016
Table 5.5 Penicillin Market Forecast by Product: Revenue ($bn), Annual Growth (%),
CAGR (%), 2017-2027
Table 5.6 Penicillin Market Forecast by Product: Market Share (%), 2017-2027

www.visiongain.com
Contents
Table 5.7 Augmentin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-
2027
Table 5.8 Zosyn/Tazocin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-
2027
Table 5.9 Unasyn Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
Table 5.10 Amoxil Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
Table 5.11 Generic Amoxicillin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%),
2017-2027
Table 5.12 Generic Amoxicillin-Clavulanic Acid Forecast: Revenue ($bn), Annual Growth
(%), CAGR (%), 2017-2027
Table 6.1 Leading Branded Fluoroquinolone Drugs: Important Facts
Table 6.2 Fluoroquinolone Market by Product: Revenue ($bn) and Market Share (%),
2016
2021
2027
Table 6.5 Fluoroquinolone Market Forecast by Product: Revenue ($bn), Annual Growth
(%), CAGR (%), 2017-2027
Table 6.6 Fluoroquinolone Market Forecast by Product: Market Share (%), 2017-2027
Table 6.7 Global Patent Expiration Dates for Avelox
Table 6.8 Avelox Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
Table 6.9 Generic Manufacturers of Levofloxacin, 2016

www.visiongain.com
Contents
Table 6.10 Cravit and Levaquin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%),
2017-2027
Table 6.11 Vigamox Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-
2027
Table 6.12 Ciprodex Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-
2027
Table 6.13 Cipro/Ciprobay Forecast: Revenue ($bn), Annual Growth (%), CAGR (%),
2017-2027
Table 6.14 Geninax Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
Table 6.15 Delafloxacin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-
2027
Table 7.1 Leading Branded Macrolides: Important Facts
Table 7.2 Macrolide Market by Product: Revenue ($bn) and Market Share (%), 2016
Table 7.5 Macrolide Market Forecast by Product: Revenues ($bn), Annual Growth (%),
CAGR (%), 2017-2027
Table 7.6 Macrolide Market Forecast by Product: Market Shares (%), 2017-2027
Table 7.7 Biaxin/Clarith Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-
2027
Table 7.8 Zithromax Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-
2027
Table 7.9 Dalacin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
Table 7.10 Dificid Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027

www.visiongain.com
Contents
Table 7.11 Solithromycin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-
2027
Table 8.1 Leading Branded Carbapenems: Important Facts
Table 8.2 Carbapenem Market by Product: Revenue ($bn) and Market Share (%), 2016
Table 8.5 Carbapenem Market Forecasts by Product: Revenues ($bn), Annual Growth
(%), CAGR (%), 2017-2027
Table 8.6 Carbapenem Market Forecast by Product: Market Share (%), 2017-2027
Table 8.7 Merrem Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
Table 8.8 Primaxin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
Table 8.9 Invanz Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
Table 8.10 Doribax Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
Table 9.1 Other Leading Branded Antibacterials: Important Facts
Table 9.2 Other Classes of Antibacterial Drugs by Product: Revenue ($bn) and Market
Share (%), 2016
Share (%), 2021
Share (%), 2027
Table 9.5 Others Market Forecasts by Product: Revenues ($bn), Annual Growth (%),
CAGR (%), 2017-2027
Table 9.6 Other Agents: Market Forecast by Product - Market Share (%), 2017-2027

www.visiongain.com
Contents
Table 9.7 Oxazolidinones in Mid to Late Stage Clinical Development, 2016
Table 9.8 Zyvox Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
Table 9.9 Cubicin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
Table 9.10 Tygacil Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
Table 9.11 TOBI/TOBI Podhaler Forecast: Revenue ($bn), Annual Growth (%), CAGR
(%), 2017-2027
Table 9.12 Solodyn Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
Table 9.13 Vibativ Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
Table 9.14 Sirturo Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
Table 9.15 Tedizolid Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-
2027
Table 9.16 Oritavancin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-
2027
Table 9.17 Dalbavancin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-
2027
Table 9.18 Surotomycin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-
2027
Table 9.19 Nemonoxacin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%),
2017-2027
Table 10.1 Antibacterial Drug Sales by National and Regional Markets: Market Size ($bn)
and Share (%), 2016
Table 10.2 Antibacterial Drug Markets: National and Regional Market Sizes ($bn), Annual
Growth (%), and CAGR (%), 2017-2027

www.visiongain.com
Contents
Table 10.3 Antibacterial Drug Markets: National and Regional Market Shares (%), 2017-
2027
Table 10.4 Incidence of Pneumonia in National Markets, 2016
Table 10.5 Incidence of Community Acquired Urinary Tract Infections in National Markets,
2016
Table 10.6 Incidence of Bacterial Skin and Skin Structure Infections in National Markets,
2016
Table 10.7 Incidence of Upper Respiratory Tract Infections in National Markets, 2016
Table 10.8 Antibacterial Drug Consumption in the Major National Markets: DDD per
Capita per Day and Absolute DDD per year, 2016
Table 10.9 Antibacterial Drug Consumption in the Smaller National Markets: DDD per
Capita per Day and Absolute DDD per year, 2016
Table 10.10 US Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth (%),
CAGR (%), 2017-2027
Table 10.11 EU Antibacterial Drugs Market Overall and by Leading Country (EU5):
Revenue Forecasts ($bn), Annual Growth (%), CAGR (%), 2017-2027
Table 10.12 Italian Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth
(%), CAGR (%), 2017-2027
Table 10.13 French Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth
(%), CAGR (%), 2017-2027
Table 10.14 German Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth
(%), CAGR (%), 2017-2027
Table 10.15 UK Early Stage Antibacterial Drug Developers, 2016
Table 10.16 UK Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth (%),
CAGR (%), 2017-2027

www.visiongain.com
Contents
Table 10.17 Spanish Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth
(%), CAGR (%), 2017-2027
Table 10.18 Japanese Antibacterial Drugs Market: Revenue Forecast ($bn), Annual
Growth (%), CAGR (%), 2017-2027
Table 10.19 South Korean Antibacterial Drugs Market: Revenue Forecast ($bn), Annual
Growth (%), CAGR (%), 2017-2027
Table 10.20 Antibacterial Drugs Market in BRIC Nations: National Revenue Forecasts
($bn), Annual Growth (%), CAGR (%), 2017-2027
Table 10.21 Chinese Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth
(%), CAGR (%), 2017-2027
Table 10.22 Indian Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth
(%), CAGR (%), 2017-2027
Table 10.23 Brazilian Antibacterial Drugs Market: Revenue Forecast ($bn), Annual
Growth (%), CAGR (%), 2017-2027
Table 10.24 Russian Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth
(%), CAGR (%), 2017-2027
Table 11.1 Small Molecule Antibacterial Drug in Phase III Development, 2016
Table 11.2 Small Molecule Antibacterial Drug in Phase II Development, 2016
Table 11.3 Inhaled Antibacterial Drug Formulations in Mid to Late Stage Clinical
Development, 2016
Table 11.4 Biological Antibacterial Therapeutics in Clinical Development, 2016
Table 12.1 Social, Technological, Economic, and Political Factors Affecting the
Antibacterial Drug Market, 2017-2027
Table 12.2 Bacterial Related Funding for BARDA, 2011-2014

www.visiongain.com
Contents
Table 13.1 World Antibacterial Drugs Market by Class: Revenues ($bn), Market Shares
(%), CAGRs (%), 2016, 2021 and 2027

www.visiongain.com
Contents
List of Figures
Figure 2.1 Leading Causes of Infectious Disease Deaths Worldwide, 2010
Figure 2.2 Key Events in the History of Antibacterial Drug Development
Figure 3.1 Historic Global Market Size ($bn), 2011-2016
Figure 3.2 Global Antibacterial Drug Market by Sector: Market Share (%), 2016
Figure 3.3 Global Antibacterial Drugs Market: Forecasted Sector (Class) Revenues ($bn),
2017-2027
Figure 3.4 Antibacterial Drugs Market: Forecasted Sector Market Shares (%), 2021
Figure 3.5 Antibacterial Drugs Market: Forecasted Sector Market Shares (%), 2027
Figure 3.6 Ten Leading Branded Antibacterial Manufacturers: Market Share (%), 2016
Figure 4.1 Cephalosporin Market by Product: Market Share (%), 2016
Figure 4.4 Cephalosporin Market Forecast: Revenue ($bn), 2017-2027
Figure 4.5 Cephalosporin Market: Drivers and Restraints, 2017-2027
Figure 4.6 Rocephin Forecast: Revenue ($bn), 2017-2027
Figure 4.7 Sulperazon Forecast: Revenue ($bn), 2017-2027
Figure 4.8 Zinnat/Ceftin Forecast: Revenue ($bn), 2017-2027
Figure 4.9 Meiact Forecast: Revenue ($bn), 2017-2027
Figure 4.10 Flomox Forecast: Revenue ($bn), 2017-2027
Figure 4.11 Zinforo/Teflaro Forecast: Revenue ($bn), 2017-2027

www.visiongain.com
Contents
Figure 4.12 Zeftera Forecast: Revenue ($bn), 2017-2027
Figure 4.13 Ceftolozane-Tazobactam Forecast: Revenue ($bn), 2017-2027
Figure 4.14 Ceftazidime-Avibactam Forecast: Revenue ($bn), 2017-2027
Figure 5.1 Penicillin Market by Product: Market Share (%), 2016
Figure 5.4 Penicillin Market Forecast: Revenue ($bn), 2017-2027
Figure 5.5 Augmentin Forecast: Revenue ($bn), 2017-2027
Figure 5.6 Zosyn/Tazocin Forecast: Revenue ($bn), 2017-2027
Figure 5.7 Unasyn Forecast: Revenue ($bn), 2017-2027
Figure 5.8 Amoxil Forecast: Revenue ($bn), 2017-2027
Figure 5.9 Generic Amoxicillin Forecast: Revenue ($bn), 2017-2027
Figure 5.10 Generic Amoxicillin-Clavulanic Acid Forecast: Revenue ($bn), 2017-2027
Figure 6.1 Fluoroquinolone Market by Product: Market Share (%), 2016
Figure 6.4 Fluoroquinolone Market Forecast: Revenue ($bn), 2017-2027
Figure 6.5 Avelox Forecast: Revenue ($bn), 2017-2027
Figure 6.6 Cravit and Levaquin Forecast: Revenue ($bn), 2017-2027
Figure 6.7 Vigamox Forecast: Revenue ($bn), 2017-2027
Figure 6.8 Ciprodex Forecast: Revenue ($bn), 2017-2027

www.visiongain.com
Contents
Figure 6.9 Cipro/Ciprobay Forecast: Revenue ($bn), 2017-2027
Figure 6.10 Geninax Forecast: Revenue ($bn), 2017-2027
Figure 6.11 Delafloxacin Forecast: Revenue ($bn), 2017-2027
Figure 7.1 Macrolide Market by Product: Market Share (%), 2016
Figure 7.4 Macrolide Market Forecast: Revenue ($bn), 2017-2027
Figure 7.5 Biaxin/Clarith Forecast: Revenue ($bn), 2017-2027
Figure 7.6 Zithromax Forecast: Revenue ($bn), 2017-2027
Figure 7.7 Dalacin Forecast: Revenue ($bn), 2017-2027
Figure 7.8 Dificid Forecast: Revenue ($bn), 2017-2027
Figure 7.9 Solithromycin Forecast: Revenue ($bn), 2017-2027
Figure 8.1 Carbapenem Market by Product: Market Share (%), 2016
Figure 8.4 Carbapenem Market Forecast: Revenue ($bn), 2017-2027
Figure 8.5 Merrem Forecast: Revenue ($bn), 2017-2027
Figure 8.6 Primaxin Forecast: Revenue ($bn), 2017-2027
Figure 8.7 Invanz Forecast: Revenue ($bn), 2017-2027
Figure 8.8 Doribax Forecast: Revenue ($bn), 2017-2027
Figure 9.1 Other Classes of Antibacterial Drugs by Product: Market Share (%), 2016

www.visiongain.com
Contents
Figure 9.4 Other Agents Market Forecast by Product: Revenue ($bn), 2017-2027
Figure 9.5 Zyvox Forecast: Revenue ($bn), 2017-2027
Figure 9.6 Cubicin Forecast: Revenue ($bn), 2017-2027
Figure 9.7 Tygacil Forecast: Revenue ($bn), 2017-2027
Figure 9.8 TOBI/TOBI Podhaler Forecast: Revenue ($bn), 2017-2027
Figure 9.9 Solodyn Forecast: Revenue ($bn), 2017-2027
Figure 9.10 Vibativ Forecast: Revenue ($bn), 2017-2027
Figure 9.11 Sirturo Forecast: Revenue ($bn), 2017-2027
Figure 9.12 Tedizolid Forecast: Revenue ($bn), 2017-2027
Figure 9.13 Oritavancin Forecast: Revenue ($bn), 2017-2027
Figure 9.14 Dalbavancin Forecast: Revenue ($bn), 2017-2027
Figure 9.15 Surotomycin Forecast: Revenue ($bn), 2017-2027
Figure 9.16 Nemonoxacin Forecast: Revenue ($bn), 2017-2027
Figure 10.1 Antibacterial Drug Sales by National and Regional Markets: Market Share
(%), 2016
Figure 10.2 Antibacterial Drug Market Forecasts: National and Regional Market Sizes
($bn), 2017-2027
Figure 10.3 Absolute Annual Antibacterial Drug Consumption by Nation, 2016
Figure 10.4 Per Capita Antibacterial Drug Consumption by Nation, 2016

www.visiongain.com
Contents
Figure 10.5 US Antibacterial Drugs Market: Revenue Forecast ($bn), 2017-2027
Figure 10.6 EU Antibacterial Drugs Market by Leading Country (EU5): Revenue
Forecasts ($bn), 2017-2027
Figure 10.7 Italian Antibacterial Drugs Market: Revenue Forecast ($bn), 2017-2027
Figure 10.8 French Antibacterial Drugs Market: Revenue Forecast ($bn), 2017-2027
Figure 10.9 German Antibacterial Drugs Market: Revenue Forecast ($bn), 2017-2027
Figure 10.10 UK Antibacterial Drugs Market: Revenue Forecast ($bn), 2017-2027
Figure 10.11 Spanish Antibacterial Drugs Market: Revenue Forecast ($bn), 2017-2027
Figure 10.12 Japanese Antibacterial Drugs Market: Revenue Forecast ($bn), 2017-2027
Figure 10.13 South Korean Antibacterial Drugs Market: Revenue Forecast ($bn), 2017-
2027
Figure 10.14 Antibacterial Drugs Market in BRIC Nations: National Revenue Forecasts
($bn), 2017-2027
Figure 10.15 Chinese Antibacterial Drugs Market: Revenue Forecast ($bn), 2017-2027
Figure 10.16 Indian Antibacterial Drugs Market: Revenue Forecast ($bn), 2017-2027
Figure 10.17 Brazilian Antibacterial Drugs Market: Revenue Forecast ($bn), 2017-2027
Figure 10.18 Russian Antibacterial Drugs Market: Revenue Forecast ($bn), 2017-2027
Figure 12.1 Strengths and Weaknesses of the Antibacterial Drug Market, 2017-2027
Figure 12.2 Opportunities and Threats for the Antibacterial Drug Market, 2017-2027
Figure 12.3 Strategies and Technologies to Prevent Hospital Acquired Infections, 2016

www.visiongain.com
Contents
Companies Mentioned
Abbott Laboratories
AbbVie
Achaogen
Actavis
Actelion
Affinium Pharmaceutical
AiCuris GmbH & Co. KG
Alcon
Alkem Laboratories
Allergan
Allied Pharma
Apotex
APP Pharmaceuticals
Aptalis Pharma
Aquapharm Biodiscovery
Aradigm
Aridis Pharmaceuticals
Ascend Therapeutics
Astellas Pharma
AstraZeneca
Aurobindo Pharma
Barr Pharmaceuticals
Basilea Pharmaceuticals
Bayer Laboratories
Biomax Biotechnics
Bristol-Myers Squibb
Cadila Healthcare
Calixa Therapeutics
Cardeas Pharma
Cellceutix
Cempra Pharmaceuticals

www.visiongain.com
Contents
Cipla
Claris Lifesciences
Cornerstone Biopharma
Cornerstone Therapeutics
Corona Remedies
Critical Therapeutics
Cubist Pharmaceuticals
Daiichi Sankyo
Dainippon Sumitomo
Discuva
Dr. Reddy’s Laboratories
Durata Therapeutics
Eli Lilly
Emcure Pharmaceuticals
Eros Pharma
Forest Laboratories
Furiex Pharmaceuticals
Gate Pharma
Gilead Sciences
Glenmark
GlycoVaxyn
GlaxoSmithKline (GSK)
Hetero
Hi-Tech Pharma
Hikma Farmaceutica
Hospira
Insmed
Intercell
Itochu Chemical Frontier
Janssen Pharmaceuticals
Johnson & Johnson
KaloBios
Kenta Biotech

www.visiongain.com
Contents
Kuhnil Pharm
Lupin
Macleod Pharmaceuticals
Medicis
MedImmune
Meiji
Melinta Therapeutics
Merck & Co.
Merlion Pharmaceuticals
Microlabs
MicuRx Pharmaceuticals
Mpex Pharmaceuticals
Mylan
Nabriva Therapeutics
Nalneva
Neiss Labs
Nektar Therapeutics
Novacta Biosystems
Novartis
Novexel
Optimer Biotechnology
Orchid Chemicals
Orchid Healthcare
Ortho-McNeil
Paratek Pharmaceuticals
Peninsula Pharmaceuticals
Pfizer
Pharmacia
Phico Therapeutics
Piramal Healthcare
Plenus Pharmaceuticals
Pliva
Polyphor

www.visiongain.com
Contents
Procarta Biosystems
Procter & Gamble Pharmaceuticals
Ranbaxy
Redx Pharma
Roche
Roxane
R-Pharma
Sagent Pharmaceuticals
Sandoz
Sanofi
Savara Pharmaceuticals
Sawai Pharmaceutical
Schering Plough
Seika Pharma
Sequella
Shanghai MengKe Pharmaceuticals
Shionogi
Shire
Sidmak Labs
Solitaire Pharmacia
Specialised Therapeutics Australia
Sunovion Pharma
TaiGen Biotechnology
Taisho Toyama
Takeda
TAP Holdings
Targanta Therapeutics
Tetraphase Pharmaceuticals
Teva Pharmaceutical Industries
The Medicines Company
Theravance
Torrent Pharmaceuticals
Trius Therapeutics

www.visiongain.com
Contents
TTY Biopharma
Unichem Laboratories
Valeant Pharmaceuticals
Vansen Pharma
ViroPharma
Warner Chilcott
Watson
Wockhardt
Zhejiang Medicine Company
Zuellig Pharma
Zydus Pharmaceuticals
Organisations Mentioned
Agência Nacional de Vigilância Sanitária (ANVISA)
Duke University
European Medicines Agency (EMA)
Food and Drug Administration (FDA)
Ministry of Health, Labour and Welfare (MHLW)
Michigan State University
National Institute for Health and Clinical Excellence (NICE)
National Institutes of Health (NIH)
University of Connecticut
World Health Organization (WHO)

www.visiongain.com Page 52
Global Antibacterial Drugs Market 2017-2027:
Cephalosporins, Penicillins, Fluoroquinolones,
Macrolides, Carbapenems and Others
Figure 2.1 Leading Causes of Infectious Disease Deaths Worldwide, 2010
Although community-acquired infections are common, healthcare-associated infections are an
increasingly concerning phenomenon in developed markets. They are reportedly the fourth leading
cause of deaths in these countries. Estimates in Europe, for example, indicate that between 1.5
and 2 million people are affected by hospital-acquired infections every year. In the US, the Centers
for Disease Control and Prevention (CDC) estimates that there are two million cases of hospital-
acquired infections in that country every year, leading to around 90,000 deaths. The costs of
treating hospital-acquired infections in the US total $5bn annually, indicating the level of concern
among healthcare payers. High incidence and mortality rates are seen in the following infections:
• CDAD, which the CDC estimates accounts for 14,000 deaths every year in the US. The
majority of these occur in patients over the age of 65. In the second half of the last decade,
however, there were 32.6 cases per 100,000 children in the US, according to data from the
Mayo Clinic.
• Streptococcus pyogenes causes around 10,000 severe infections in the US every year,
with close to 15% of cases resulting in death. In Northern Europe, the bacteria cause
severe disease in 3 out of every 100,000 people each year.
Respiratory Tract
Infections
43.5%
Diarrhoeal
Diseases
22.3%
Tuberculosis
18.5%
Meningitis
6.5%
Others
9.1%
Source: visiongain 2017 Global Burden of Disease Study 2010, Lancet, 2014

Zerbraxa (ceftolozane) Merck 2015 2025 IV
Fortaz/Tazicef (ceftazidime) Hospira 1984 1994 IV, IM
4.1 Cephalosporins Market 2016 – No Dominant Brands
In 2016, the cephalosporin submarket was the largest sector of the antibacterial drugs market,
accounting for 27.3% of the global antibacterial drug market at revenue of of $11.39bn. The three
highest earing brands are in this class are Pfizer’s Sulperazon, Takeda’s Teflaro and Roche’s
Rocephin. In 2016, these drugs achieved revenues of $0.29bn, $0.51bn and $0.29bn and
accounting for 2.5%, 4.5% and 2.5% of the submarket respectively (Table 4.2 and Figure 4.1).
As the one of the most widely prescribed classes of antibiotic, high prescription rates have
maintained the cephalosporins ranking as the leading sector of the antibacterial drugs market,
despite significant generic penetration in this subsector. In 2016, the value of the cephalosporin
market rose slightly, driven by revenue growth for Sulperazon, Zinforo (ceftaroline), and worldwide
demands for generics. Growth was hampered by continued generic competition for branded
products, including: Flomox and Ceftin/Zinnat.
Table 4.2 Cephalosporin Market by
Product: Revenue ($bn) and Market
Share (%), 2016
Drug
Revenue
($bn)
Market
Share (%)
Rocephin 0.29 2.5
Sulperazon 0.29 2.5
Ceftin/Zinnat 0.24 2.1
Meiact 0.17 1.5
Flomox 0.08 0.7
Teflaro 0.51 4.5
Zeftera 0.08 0.7
Zerbraxa 0.17 1.5
Fortaz/Tazicef 0.16 1.4
Others 9.40 82.5
Total Cephalosporins 11.39 100.0
Source: visiongain 2017, Drugs.com
Source: visiongain 2017

5.8 Amoxil (Amoxicillin) – A Historic Antibacterial Brand
Amoxil is a semi synthetic penicillin antibiotic launched on the market in 1972. The drug comes in
oral suspensions of 40 and 80mg/ml in addition to tablet of 500 and 875mg. Amoxicillin is a first
line treatment for a number of conditions and is the most prescribed antibacterial in Western
Europe. Amoxil remains a strong brand worldwide and even without patent protection sales have
been stable in recent years. Even still, GSK has been divesting various segments of its established
businesses. In November 2010, they sold the entire US amoxicillin business to Dr. Reddy’s. This
sale included Amoxil as well as Augmentin and associated manufacturing facilities. GSK followed
up this sale with a divestment of Australia rights for “classic brands”, including Amoxil, to Aspen
apparently for $172m in cash.
5.8.1 Marginal Decline in Revenue - Forecast 2017-2027
Revenue for branded Amoxil has been steadily declining for years due to generic price
competition. For 2016, an estimated of $0.20bn was generated from worldwide sales, a 2.0%
decline from the previous year. Visiongain estimates that revenue will continue to decline over the
forecast period as bacterial resistance to Amoxil will increase across all markets. Additionally, a
number of highly efficacious generics will enter the market and compete for market share. In 2021
revenue will have fallen to $0.16bn, and by 2027 it will have fallen further to $0.11bn, falling at a
CAGR of -6.1% over the second half of the forecast period (Table 5.10 and Figure 5.8).
Table 5.10 Amoxil Forecast: Revenue ($bn), Annual Growth (%), CAGR (%),
2017-2027
2016 2017 2018 2019 2020 2021
Amoxil ($bn) 0.20 0.19 0.18 0.18 0.17 0.16
Annual Growth (%) -3.0 -3.0 -4.0 -4.0 -4.0
CAGR (%) -4.4
2022 2023 2024 2025 2026 2027
Amoxil ($bn) 0.15 0.15 0.14 0.13 0.12 0.11
Annual Growth (%) -5.0 -5.0 -5.0 -6.9 -7.7 -8.3
CAGR (%) -6.1
Source: visiongain 2017 – CAGR values for period 2016-2021 and 2021-2027

Global Antibacterial Drugs Market 2017-2027

Recommended

Recommended

More Related Content

What's hot

What's hot (20)

Similar to Global Antibacterial Drugs Market 2017-2027

Similar to Global Antibacterial Drugs Market 2017-2027 (19)

Recently uploaded

Recently uploaded (20)

Global Antibacterial Drugs Market 2017-2027